Esperion Therapeutics Inc. (ESPR) has upgraded its 2026 financial outlook following two new strategic agreements, including a licensing deal with a global pharmaceutical company and a collaborative development pact focused on novel lipid-lowering therapies. The updates reflect stronger commercial and pipeline momentum.
- Esperion Therapeutics raised 2026 revenue guidance to $675M–$700M, up from $620M–$650M
- New licensing agreement includes up to $150M in milestone payments for Asian market access
- Collaboration with academic institution secured $25M in R&D funding over five years
- Nexletol revenue grew 18% YoY in Q4 2025, driving commercial momentum
- ESPR shares rose 8.3% in after-hours trading following guidance update
- Sector-wide ETFs XLV and IHI registered elevated trading activity
Esperion Therapeutics Inc. (ESPR) has revised its full-year 2026 revenue guidance upward to a range of $675 million to $700 million, up from the previous forecast of $620 million to $650 million. The company cited the successful execution of two key strategic agreements as the primary driver of this enhanced outlook. The first agreement involves a licensing deal with a multinational pharmaceutical partner for the commercialization of a next-generation PCSK9 inhibitor in select Asian markets, expected to generate milestone payments totaling up to $150 million upon regulatory approval and sales targets. The second agreement is a research collaboration with an academic medical center to advance novel therapies targeting high-risk atherosclerotic cardiovascular disease, with $25 million in upfront and milestone funding committed over five years. The company’s updated guidance reflects increased expectations for its flagship product, bempedoic acid (brand name Nexletol), which recorded 18% year-over-year revenue growth in Q4 2025. The expanded commercial footprint, supported by the new international licensing arrangement, is expected to drive revenue penetration in Japan, South Korea, and Singapore. Additionally, the pipeline collaboration is anticipated to yield a Phase 2 clinical data readout in late 2027, potentially broadening the company's therapeutic reach. The positive guidance shift has been met with a favorable market reaction, with ESPR shares rising 8.3% in after-hours trading following the announcement. Analysts note that the strengthened business outlook reduces execution risk and enhances the company’s ability to fund internal R&D. The stock’s performance remains closely tied to broader healthcare sector trends, with ETFs such as XLV and IHI showing corresponding upticks in trading volume and investor interest.